Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project

Bone Marrow Transplantation volume 40, pages 185–192 (2007)Cite this article

Abstract

Granulocyte-colony stimulating factor (G-CSF) is widely administered to donors who provide peripheral blood stem cells (PBSC) for individuals who undergo hematopoietic stem cell transplants. Questions have been raised about the safety of G-CSF in this setting. Herein, the Research on Adverse Drug Events and Reports (RADAR) project investigators reviewed the literature on G-CSF-associated adverse events in healthy individuals or persons with chronic neutropenia or cancer. Toxicities identified included bone pain and rare instances of splenic rupture, allergic reactions, flares of underlying autoimmune disorders, lung injury and vascular events. Among healthy individuals, four patients developed splenic rupture shortly after G-CSF administration and three patients developed acute myeloid leukemia 1 to 5 years after G-CSF administration. Registry studies identified no increased risks of malignancy among healthy individuals who received G-CSF before PBSC harvesting. However, more than 2000 donors would have to be followed for 10 years to detect a 10-fold increase in leukemia risk. Our review identifies bone pain as the most common toxicity of G-CSF administration. There are questions about a causal relationship between G-CSF administration and acute leukemia, but more long-term safety data from database registries are needed to adequately evaluate such a relationship.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Pulsipher MA, Nagler A, Iannone R, Nelson RM . Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 2006; 46: 422–433.

    Article  Google Scholar 

  2. Horowitz MM, Confer DL . Evaluation of hematopoietic stem cell donors. Hematology American Society of Hematology Education Program Book, 2005, pp 469–475.

    Article  Google Scholar 

  3. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher M et al. Hematologic malignancies developing in previously healthy individuals who received hematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135: 642–650.

    Article  CAS  Google Scholar 

  4. Verdijk RM . Thrombopoietin in healthy donors. Blood 2002; 99: 3867, author reply 3867–3868.

    Article  CAS  Google Scholar 

  5. Donadieu J . Is G-CSF-mobilized peripheral stem cell harvest harmful? Pediatr Blood Cancer 2006; 48: 594–595.

    Google Scholar 

  6. Pulsipher M . RE: is G-CSF-mobilized peripheral stem cell harvest harmful? Pediatr Blood Cancer 2006; 48: 595–596.

    Google Scholar 

  7. Pentz RD . Healthy sibling donation of G-CSF primed stem cells: a call for research. Pediatr Blood Cancer 2006; 46: 407–408.

    Article  Google Scholar 

  8. Goldman JM, Madrigal JA, Pamphilon D . Possible harmful effects of short course granulocyte colony-stimulating factor in normal donors. Br J Haematol 2006; 135: 651–652.

    Article  CAS  Google Scholar 

  9. Touw IP, Bontenbal M . Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 2007; 99: 183–186.

    Article  CAS  Google Scholar 

  10. Bennett CL, Nebeker JR, Lyons EA, Samore MH, Feldman MD, McKoy JM et al. The Research on Adverse Drug Events and Reports (RADAR) project. J Am Med Assoc 2005; 293: 2131–2140.

    Article  CAS  Google Scholar 

  11. Bennett C, Nebeker JR, Yarnold PR, Tigue CC, Dorr DA, McKoy JM et al. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 2007; 167: 1041–1049.

    Article  Google Scholar 

  12. Anderlini P, Donato M, Chan KW, Huh YO, Gee AP, Lauppe MJ et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the MD Anderson Cancer Center experience. Transfusion 1999; 39: 555–560.

    Article  CAS  Google Scholar 

  13. Beelen DW, Ottinger H, Kolbe K, Ponisch W, Sayer HG, Knauf W et al. Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study. Ann Hematol 2002; 81: 701–709.

    Article  CAS  Google Scholar 

  14. Martino M, Morabito F, Callea I, Pontari A, Irrera G, Pucci G et al. Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor. Transfus Med 2005; 15: 323–328.

    Article  CAS  Google Scholar 

  15. Martino M, Console G, Irrera G, Callea I, Condemi A, Dattola A et al. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher 2005; 20: 129–136.

    Article  Google Scholar 

  16. Murata M, Harada M, Kato S, Takahashi S, Ogawa H, Okamoto S et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999; 24: 1065–1071.

    Article  CAS  Google Scholar 

  17. Kroschinsky F, Hundertmark J, Mauersberger S, Hermes M, Poppe-Thiede K, Rutt C et al. Severe autoimmune hyperthyroidism after donation of growth factor-primed allogeneic peripheral blood progenitor cells. Haematologica 2004; 89: ECR05.

    PubMed  Google Scholar 

  18. de Luis DA, Romero E . Reversible thyroid dysfunction with filgrastim. Lancet 1996; 348: 1595–1596.

    Article  CAS  Google Scholar 

  19. Hoekman K, von Blomberg-van der Flier BM, Wagstaff J, Drexhage HA, Pinedo HM . Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541–542.

    Article  CAS  Google Scholar 

  20. Van Hoef ME, Howell A . Risk of thyroid dysfunction during treatment with G-CSF. Lancet 1992; 340: 1169–1170.

    Article  CAS  Google Scholar 

  21. Duarte R, De Luis DA, Lopez-Jimenez J, Roy G, Garcia A . Thyroid function and autoimmunity during treatment with G-CSF. Clin Endocrinol (Oxf) 1999; 51: 133–134.

    Article  CAS  Google Scholar 

  22. Ehninger G . German Donor Registry Program. Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical, and Ethical Issues. Arlington, VA, September 2, 2004.

    Google Scholar 

  23. Stroncek DF, Dittmar K, Shawker T, Heatherman A, Leitman SF . Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. J Transl Med 2004; 2: 25.

    Article  Google Scholar 

  24. Stroncek D, Shawker T, Follmann D, Leitman SF . G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. Transfusion 2003; 43: 609–613.

    Article  CAS  Google Scholar 

  25. Platzbecker U, Prange-Krex G, Bornhauser M, Koch R, Soucek S, Aikele P et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184–189.

    Article  CAS  Google Scholar 

  26. Nuamah NM, Goker H, Kilic YA, Dagmoura H, Cakmak A . Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature.. Haematologica 2006; 91 (Suppl 5): ECR08.

    PubMed  Google Scholar 

  27. Falzetti F, Aversa F, Minelli O, Tabilio A . Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999; 353: 555.

    CAS  PubMed  Google Scholar 

  28. Dincer AP, Gottschall J, Margolis DA . Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004; 26: 761–763.

    Article  Google Scholar 

  29. Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J . Splenic rupture after granulocyte-colony-stimulating factor mobilization in a peripheral blood progenitor cell donor. Transfusion 2004; 44: 1260–1261.

    Article  Google Scholar 

  30. Kasper C, Jones L, Fujita Y, Morgenstern GR, Scarffe JH, Chang J . Splenic rupture in a patient with acute myeloid leukemia undergoing peripheral blood stem cell transplantation. Ann Hematol 1999; 78: 91–92.

    Article  CAS  Google Scholar 

  31. Pitini V, Ciccolo A, Arrigo C, Aloi G, Micali C, La Torre F . Spontaneous rupture of spleen during periferal blood stem cell mobilization in a patient with breast cancer. Haematologica 2000; 85: 559–560.

    CAS  PubMed  Google Scholar 

  32. O’Malley DP, Whalen M, Banks PM . Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol 2003; 73: 294–295.

    Article  Google Scholar 

  33. Arshad M, Seiter K, Bilaniuk J, Qureshi A, Patil A, Ramaswamy G et al. Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim. J Clin Oncol 2005; 23: 8533–8534.

    Article  Google Scholar 

  34. Hatzimichael E, Benetatos L, Stebbing J, Kapsali E, Panayiotopoulou S, Bourantas KL . Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. Clin Lab Haematol 2006; 28: 416–418.

    Article  CAS  Google Scholar 

  35. Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 69–70.

    Article  CAS  Google Scholar 

  36. Watring NJ, Wagner TW, Stark JJ . Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 2007; 25: 247–248.

    Article  Google Scholar 

  37. Yoshida I, Matsuo K, Teshima T, Hashimoto D, Tanimoto Y, Harada M et al. Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation. Transfusion 2006; 46: 186–192.

    Article  CAS  Google Scholar 

  38. Arimura K, Inoue H, Kukita T, Matsushita K, Akimot M, Kawamata N et al. Acute lung injury in a healthy donor during mobilization of peripheral blood stem cells using granulocyte-colony stimulating factor alone. Haematologica 2005; 90: ECR10.

    PubMed  Google Scholar 

  39. Makita K, Ohta K, Mugitani A, Hagihara K, Ohta T, Yamane T et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33: 661–665.

    Article  CAS  Google Scholar 

  40. Cavallaro AM, Lilleby K, Majolino I, Storb R, Appelbaum FR, Rowley SD et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25: 85–89.

    Article  CAS  Google Scholar 

  41. Tassi C, Tazzari PL, Bonifazi F, Giudice V, Nannetti A, Ricci F et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 36: 289–294.

    Article  CAS  Google Scholar 

  42. Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS . Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 2002; 30: 661–663.

    Article  CAS  Google Scholar 

  43. Sakamaki S, Matsunaga T, Hirayama Y, Kuga T, Niitsu Y . Haematological study of healthy volunteers 5 years after G-CSF. Lancet 1995; 346: 1432–1433.

    Article  CAS  Google Scholar 

  44. Smith RE, Bryant J, DeCillis A, Anderson S . Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003; 21: 1195–1204.

    Article  CAS  Google Scholar 

  45. Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99: 196–205.

    Article  CAS  Google Scholar 

  46. Donadieu J, Boutard P, Bernatowska E, Tchernia G, Couillaud G, Philippe N et al. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group. Eur J Pediatr 1997; 156: 693–700.

    Article  CAS  Google Scholar 

  47. Dale DC, Cottle TE, Fier CJ, Bolyard AA, Bonilla MA, Boxer LA et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72: 82–93.

    Article  Google Scholar 

  48. Hasenclever D, Sextro M . Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996; 17 (Suppl 2): S28–S30.

    PubMed  Google Scholar 

  49. Confer DL, Miller JP . Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007; 137: 77–78.

    Article  Google Scholar 

  50. Bacher U, Zander AR . Long-term safety of filgrastim (rhG-CSF) administration: application of haematopoietic growth factors in healthy individuals. Br J Haematol 2007; 137: 78–79.

    Article  Google Scholar 

  51. Rosenthal J, Healey T, Ellis R, Gillan E, Cairo MS . A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life. J Pediatr 1996; 128: 135–137.

    Article  CAS  Google Scholar 

  52. Storek J, Dawson MA, Maloney DG . Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. Blood 2000; 95: 2993–2994.

    CAS  PubMed  Google Scholar 

  53. Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628–4635.

    Article  CAS  Google Scholar 

  54. Donadieu J, Leblanc T, Bader Meunier B, Barkaoui M, Fenneteau O, Bertrand Y et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005; 90: 45–53.

    PubMed  Google Scholar 

  55. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L . Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32: 122–130.

    Article  CAS  Google Scholar 

  56. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R . Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003; 73: 33–36.

    Article  CAS  Google Scholar 

  57. Kaplinsky C, Trakhtenbrot L, Hardan I, Reichart M, Daniely M, Toren A et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32: 31–34.

    Article  CAS  Google Scholar 

  58. Rutella S, Rumi C, Pierelli L, Morosetti R, Sica S, Bonanno G et al. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol 2000; 28: 612–625.

    Article  CAS  Google Scholar 

  59. Hernandez JM, Castilla C, Gutierrez NC, Isidro IM, Delgado M, de las Rivas J et al. Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19: 1088–1091.

    Article  CAS  Google Scholar 

  60. Dong F, Brynes RK, Tidow N, Welte K, Lowenberg B, Touw IP . Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. New Engl J Med 1995; 333: 487–493.

    Article  CAS  Google Scholar 

  61. Ancliff PJ, Gale RE, Liesner R, Hann I, Linch DC . Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapy. Br J Haematol 2003; 120: 685–690.

    Article  CAS  Google Scholar 

  62. Confer D . Adult Allodonor Stem Cell Collection Safety Issues. Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical, and Ethical Issues. Arlington, VA, 2004.

    Google Scholar 

  63. Bortin MM, D’Amaro J, Bach FH, Rimm AA, van Rood JJ . HLA associations with leukemia. Blood 1987; 70: 227–232.

    CAS  PubMed  Google Scholar 

  64. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR . Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 2006; 46: 414–421.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Professor Alois Gratwohl for unpublished information from the EBMT data and for helpful comments on earlier drafts of this manuscript. This work was supported in part by grants from the National Cancer Institute (1 R01CA 102713-01 and P 30 CA60553 to Drs Bennett and McKoy).

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    C C Tigue, A M Evens, S M Trifilio, M S Tallman & C L Bennett

  2. The Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA

    C C Tigue, J M McKoy & C L Bennett

  3. The VA Center for Management of Complex Chronic Care, Jesse Brown VA Medical Center, Chicago, IL, USA

    C C Tigue & C L Bennett

  4. Division of Geriatric Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

    J M McKoy

Authors
  1. C C Tigue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J M McKoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A M Evens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S M Trifilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M S Tallman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C L Bennett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C L Bennett.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tigue, C., McKoy, J., Evens, A. et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 40, 185–192 (2007). https://doi.org/10.1038/sj.bmt.1705722

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705722

Keywords

This article is cited by

Search

Advanced search

Quick links